U.S. Markets closed
  • Gold

    1,734.70
    -2.80 (-0.16%)
     
  • Silver

    22.46
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1690
    +0.0001 (+0.0117%)
     
  • 10-Yr Bond

    1.5340
    +0.2100 (+15.86%)
     
  • Vix

    23.25
    -1.11 (-4.56%)
     
  • GBP/USD

    1.3544
    +0.0004 (+0.0271%)
     
  • USD/JPY

    111.5550
    +0.0750 (+0.0673%)
     
  • BTC-USD

    41,080.34
    -1,177.61 (-2.79%)
     
  • CMC Crypto 200

    1,014.75
    -25.73 (-2.47%)
     
  • FTSE 100

    7,028.10
    +47.12 (+0.67%)
     
  • Nikkei 225

    30,183.96
    +344.26 (+1.15%)
     

Should You Take Comfort From Insider Transactions At PTC Therapeutics, Inc. (NASDAQ:PTCT)?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell PTC Therapeutics, Inc. (NASDAQ:PTCT), you may well want to know whether insiders have been buying or selling.

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, most countries require that the company discloses such transactions to the market.

We don't think shareholders should simply follow insider transactions. But it is perfectly logical to keep tabs on what insiders are doing. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise'.

See our latest analysis for Therapeutics

The Last 12 Months Of Insider Transactions At Therapeutics

In the last twelve months, the biggest single purchase by an insider was when Independent Chairman of the Board Michael Schmertzler bought US$325k worth of shares at a price of US$32.48 per share. We do like to see buying, but this purchase was made at well below the current price of US$45.60. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership of Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 0.4% of Therapeutics shares, worth about US$13m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At Therapeutics Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Therapeutics and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Therapeutics. At Simply Wall St, we found 2 warning signs for Therapeutics that deserve your attention before buying any shares.

Of course Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.